Table 2.
Frequency of Biomarker Elevations in 156 Children With High-Risk Acute Lymphoblastic Leukemia, by Treatment Group and Study Interval
| Biomarker and Study Interval | Doxorubicin |
Dexrazoxane-Doxorubicin |
P* | ||
|---|---|---|---|---|---|
| % | No. of Patients With Elevations/No. of Patients | % | No. of Patients With Elevations/No. of Patients | ||
| cTnT† | |||||
| Any increase | 50.7 | 38/75 | 27.1 | 22/81 | .003 |
| Before doxorubicin therapy | 11.7 | 6/51 | 12.7 | 7/55 | .99 |
| During doxorubicin therapy | 46.6 | 35/75 | 20.0 | 16/80 | < .001 |
| After doxorubicin therapy | 46.6 | 14/30 | 12.5 | 4/32 | .005 |
| Multiple increases | 40.0 | 30/75 | 13.4 | 11/81 | < .001 |
| NT-proBNP‡ | |||||
| Any increase | 100 | 70/70 | 86.3 | 63/73 | .001 |
| Before doxorubicin therapy | 88.8 | 32/36 | 91.8 | 34/37 | .71 |
| During doxorubicin therapy | 98.5 | 68/69 | 84.9 | 62/73 | .005 |
| After doxorubicin therapy | 48.0 | 12/25 | 20.0 | 4/20 | .07 |
| Multiple increases | 90.4 | 66/73 | 78.0 | 57/73 | .007 |
| hsCRP§ | |||||
| Any increase | 95.7 | 67/70 | 89.0 | 65/73 | .20 |
| Before doxorubicin therapy | 83.3 | 30/36 | 81.0 | 30/37 | .99 |
| During doxorubicin therapy | 95.6 | 66/69 | 87.6 | 64/73 | .13 |
| After doxorubicin therapy | 45.8 | 11/24 | 42.1 | 8/19 | .99 |
| Multiple increases | 88.5 | 62/70 | 76.7 | 56/73 | .08 |
Abbreviations: cTnT, cardiac troponin T; hsCRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide.
*
Fisher's exact test.
†
Increased cTnT defined as > 0.01 ng/mL.
‡
Increased NT-proBNP defined as ≥ 100 pg/mL in patients ≥ 1 year old and ≥ 150 pg/mL in patients < 1 year old.
§
Increased hsCRP defined as ≥ 1.9 mg/L.